Breno Moreno de Gusmão, Vice Clinical Director at BP Mirante, BP – A Beneficência Portuguesa de São Paulo, shared a post on X:
“Systematic review of 11 MAICs in triple-class exposed RRMM: linvoseltamab and cilta-cel consistently outperformed comparators across ORR, ≥CR, DOR, PFS, and OS. No head-to-head trials exist—indirect comparisons only, interpret cautiously.”
Title: A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma
Authors: Naresh Bumma, Hans C. Lee, Joshua Richter, James E. Hoffman, Jeffrey A. Zonder, Mirko Fillbrunn, Viviana Garcia-Horton, Zheng-Yi Zhou, Yingxin Xu, Heather Burnett, James Harnett, Timothy J. Inocencio, Michelle Little, Katherine Knorr, Glenn S. Kroog, Wanning Xu, Qiufei Ma, Sundar Jagannath
Read the article here.
Other articles about Multiple Myeloma on OncoDaily.